154 related articles for article (PubMed ID: 19265346)
1. The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice.
Walker-Bone K; Wood A; Hull R; Ledingham JM; McCrae FC; Shaban R; Thomas A; Mackay K
Clin Med (Lond); 2004; 4(5):431-6. PubMed ID: 15536872
[TBL] [Abstract][Full Text] [Related]
2. Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis.
Ozen G; Kamen DL; Mikuls TR; England BR; Wolfe F; Michaud K
Arthritis Care Res (Hoboken); 2018 May; 70(5):713-723. PubMed ID: 28771973
[TBL] [Abstract][Full Text] [Related]
3. Pharmacist-initiated interventions to test quantitative bone mineral density and prescribe osteoporosis medications to prevent steroid-induced osteoporosis.
Hirose T; Mori K; Kimura M; Yamashita S; Hayashi H; Usami E; Tanase T
Pharmazie; 2024 Jun; 79(6):124-128. PubMed ID: 38877679
[TBL] [Abstract][Full Text] [Related]
4. Audits of the prevention and treatment of corticosteroid-induced osteoporosis in outpatients with rheumatic diseases in the West Midlands.
Paskins Z; Potter T; Erb N; Obrenovic K; Rowe IF;
Clin Med (Lond); 2006; 6(2):183-7. PubMed ID: 16688979
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist.
Chakrabarti K; McCune WJ
Curr Opin Rheumatol; 2023 May; 35(3):161-169. PubMed ID: 36943706
[TBL] [Abstract][Full Text] [Related]
6. Secondary prevention of fragility fractures: are we following the guidelines? Closing the audit loop.
Prasad N; Sunderamoorthy D; Martin J; Murray JM
Ann R Coll Surg Engl; 2006 Sep; 88(5):470-4. PubMed ID: 17002853
[TBL] [Abstract][Full Text] [Related]
7. Self-reported osteoporosis prevention in inhaled corticosteroid users in community pharmacy setting.
Chan V; Cave AJ; Banh HL
SAGE Open Med; 2015; 3():2050312115586912. PubMed ID: 26770786
[TBL] [Abstract][Full Text] [Related]
8. Comments about treatment of glucocorticoid-induced osteoporosis.
Messina OD
Reumatol Clin (Engl Ed); 2024 Feb; 20(2):113. PubMed ID: 38331664
[No Abstract] [Full Text] [Related]
9. Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users.
Bjornsdottir HH; Einarsson ÓB; Gröndal G; Gudbjornsson B
SAGE Open Med; 2024; 12():20503121241235056. PubMed ID: 38516640
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease.
Bankole A; Greear EL
Eur J Rheumatol; 2023 Jul; 10(3):97-100. PubMed ID: 37681255
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid prescribing in neurology.
Jones AP; Debono M; Walsh J; Smith C; Hunt L; McKevitt FM
Pract Neurol; 2024 Mar; ():. PubMed ID: 38553045
[TBL] [Abstract][Full Text] [Related]
12. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.
Cheng CH; Chen LR; Chen KH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163300
[TBL] [Abstract][Full Text] [Related]
13. Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.
Safi MA; Fathaldin OA
Saudi Med J; 2015 Mar; 36(3):316-23. PubMed ID: 25737174
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Elshal MF; Almalki AL; Hussein HK; Khan JA
Afr J Tradit Complement Altern Med; 2013; 10(5):267-73. PubMed ID: 24311835
[TBL] [Abstract][Full Text] [Related]
15. Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend.
Al-Bishri J; Attar S; Bassuni N; Al-Nofaiey Y; Qutbuddeen H; Al-Harthi S; Subahi S
Clin Med Insights Arthritis Musculoskelet Disord; 2013; 6():11-8. PubMed ID: 23645988
[TBL] [Abstract][Full Text] [Related]
16. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice.
Ledwich LJ; Clarke K
J Clin Rheumatol; 2009 Mar; 15(2):61-4. PubMed ID: 19265346
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
19. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
